Home | Sitemap | Search | ContactA- A A+
   
 
    Public Member Support us  
 

IBCSG 55-17 TOUCH 

Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer.

DESIGN

please click on the picture to see a larger version

Trial Co-Chairs info
Laura Biganzole, MD, Prato, Italy
Etienne Brain, MD, PhD, Paris, France

Lead Trial Coordinator
Holly Shaw

Data Manager
Susan Fischer

Trial Monitors
Giuseppe Achille, Daniela Celotto, Carmen Comune, Magdalena Sánchez-Hohl, Lionel Nobs, Mariana Pardo Contreras, Isabelle Zenklusen

IBCSG Data Management Center/FSTRF
4033 Maple Road
Amherst, New York 14226 USA
Phone: +1 716 834 0900
Fax: +1 716 833 3990
Email:
ibcsg55_TOUCH@fstrf.org

IBCSG Coordinating Center, Bern, Switzerland
Phone: +41 31 511 94 00
Fax: +41 31 511 94 01
Email:
TOUCH-monitoring@ibcsg.org

Date of Activation
Feb 28, 2018 

Targeted Accrual
144


News

08.09.2019:
8.9.2019 - RACE FOR LIFE, Bundesplatz Bern

16.06.2019:
33. SCHWEIZER FRAUENLAUF 16. Juni 2019 woman 4 woman - walking together, stronger than ever

22.05.2019:
PINK GOLFTOUR 2019

All News

 
  Print